


# Human CellExp™ TNFSF11 / RANKL / CD254, Human Recombinant

<b>CATALOG NO:</b>	P1206-10            10 µg P1206-50            50 µg
<b>ALTERNATE NAMES:</b>	RANKL, CD254, TRANCE, OPGL, ODF
<b>SOURCE:</b>	HEK 293 cells (Gly 64 - Asp 245)
<b>PURITY:</b>	> 95% by SDS – PAGE
<b>MOL. WEIGHT:</b>	This protein carries a polyhistidine tag at the N-terminus. The protein has a calculated MW of 23.1 kDa. The protein migrates as 30-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
<b>ENDOTOXIN LEVEL:</b>	< 1.0 EU per 1µg of protein (determined by LAL method)
<b>FORM:</b>	Lyophilized
<b>FORMULATION:</b>	Lyophilized from 0.22 µm filtered solution in PBS, pH7.4. Generally Mannitol or Trehalose is added as a protectant before lyophilization.
<b>STORAGE CONDITIONS:</b>	Store at -20°C. After reconstitution, aliquot and store at -20°C and use within 3 months. Avoid repeated freezing and thawing cycles.
<b>RECONSTITUTION:</b>	Centrifuge the vial prior to opening. Reconstitute in sterile deionized water to a concentration of 50 µg/ml. Solubilize for 30 to 60 minutes at room temperature with occasional gentle mixing. Carrier protein (0.1% (W/V) HSA or BSA) is recommended for further dilution and long term storage. Do not vortex. This solution can be stored at 2-8°C for up to 1 month.
<b>DESCRIPTION:</b>	Receptor activator of nuclear factor kappa-B ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF), is known as a type II membrane protein and is a member of the tumor necrosis factor (TNF) superfamily. RANKL, through its ability to stimulate osteoclast formation and activity, is a critical mediator of bone resorption and overall bone density. Some findings also suggestion some cancer cells, particularly prostate cancer cells, can activate an increase in bone remodeling and ultimately increase overall bone production. This increase in bone remodeling and bone production increases the overall growth of bone metastasizes.
<b>SPECIFIC ACTIVITY:</b>	Immobilized Human TNFRSF11A at 5 µg/mL (100 µL/well) can bind Human TNFSF11, His Tag with a linear range of 0.2-6 ng/mL

A



B




Fig. A. Human TNFSF11, His Tag on SDS-PAGE under reducing (R) condition.

Fig. B. Immobilized Human TNFRSF11A at 5 µg/mL (100 µL/well) can bind Human TNFSF11, His Tag with a linear range of 0.2-6 ng/mL

## RELATED PRODUCT:

- Human CellExp™ TNFRSF10B /TRAILR2, human recombinant (Cat. No. 7448-10)
- Human CellExp™ CD155, human recombinant (Cat. No. 7462-10, -50)
- Human CellExp™ CD160/BY55, human recombinant (Cat. No. 7386-10, -50)
- Human CellExp™ CD166/ ALCAM, human recombinant (Cat. No. 7437-10, -50)
- Human CellExp™ CD172A / SIRP, human recombinant (Cat. No. 7506-10, -50)
- Human CellExp™ CD33 / SIGLEC-3, human recombinant (Cat. No. 7370-10, -50)
- Human CellExp™ CD47, human recombinant (Cat. No. 7385-10, -50)
- Human CellExp™ CD55/DAF, human recombinant (Cat. No. 7432-10, -50)
- Human CellExp™ CD58 /LFA-3, human recombinant (Cat. No. 7427-10, -50)
- Human CellExp™ CD62E/E-Selectin, human recombinant (Cat. No. 7434-20, -100)
- Human CellExp™ CD71 / TFRC / TFR, human recombinant (Cat. No. 7279-10, -50)
- Human CellExp™ CD273, human recombinant (Cat. No. 7369-10, -50)
- Human CellExp™ CD36, human recombinant (Cat. No. 7371-10, -50)
- Human CellExp™ CD87, human recombinant (Cat. No. 7372-20, -100)

**FOR RESEARCH USE ONLY! Not to be used on humans.**